% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Geurts:1053900,
      author       = {Geurts, Marjolein and LeRhun, Emilie and Minniti, Giuseppe
                      and Padovan, Marta and Duerinck, Johnny and Franceschi,
                      Enrico and Touat, Mehdi and Pace, Andrea and Sahm, Felix and
                      Furtner, Julia and Albert, Nathalie and Lohman, Philipp and
                      van Zandvoort, Martine and Quoilin, Caroline and Daumer,
                      Corinne and Koh, Eng-Siew and Pitz, Marshall and Gorlia,
                      Thierry and Weller, Michael and van den Bent, Martin and
                      Preusser, Matthias},
      title        = {{CTNI}-09. {VORASIDENIB} {AS} {MAINTENANCE} {TREATMENT}
                      {AFTER} {FIRST}-{LINE} {CHEMORADIOTHERAPY} {IN}
                      {IDH}-{MUTANT} {GRADE} 2/3 {ASTROCYTOMA}: {STUDY} {PROTOCOL}
                      {FOR} {THE} {PLACEBO}-{CONTROLLED}, {TRIPLE}-{BLIND},
                      {RANDOMIZED} {PHASE} {III} {STUDY} {EORTC}-2427 ({VIGOR})},
      issn         = {1523-5866},
      reportid     = {FZJ-2026-01598},
      year         = {2025},
      abstract     = {AbstractBACKGROUNDThe efficacy of vorasidenib as
                      maintenance therapy after completion of standard of care
                      remains unclear. The VIGOR trial will investigate the
                      efficacy of adding vorasidenib as maintenance therapy after
                      completion of standard radiochemotherapy in patients with
                      astrocytoma, IDH-mutant, WHO grade 2 or 3.MATERIAL AND
                      METHODSVIGOR is a comparative, randomized (1:1),
                      triple-blinded, multicentre phase III superiority trial. A
                      total of 468 adult patients with an astrocytoma, IDH-mutant,
                      WHO grade 2 or 3, at least one prior neurosurgery, who were
                      in need for radiochemotherapy and completed standard of care
                      radiotherapy followed by chemotherapy will be randomized
                      between placebo or vorasidenib monotherapy 40 mg once daily
                      until disease progression, unacceptable toxicity, or
                      withdrawal of patient consent for up to 5 years. The primary
                      objective is to demonstrate that vorasidenib maintenance
                      therapy improves locally assessed PFS from enrolment
                      compared to placebo. Primary endpoint is PFS from
                      randomization, patients are randomized upon completion of
                      the adjuvant chemotherapy. Secondary endpoints include PFS
                      from start of radiotherapy, overall survival, time to next
                      intervention, toxicity, health related quality of life,
                      neurological symptoms and neurocognitive function.
                      Translational research including tissue samples, liquid
                      biopsies, and neuroimaging data is planned. Patients will be
                      enrolled in 10 European countries (European Organisation for
                      Research and Treatment of Cancer (EORTC) sites), Australia
                      (Cooperative Trials Group for Neuro-Oncology (COGNO) sites)
                      and Canada (Canadian Cancer Trials Group (CCTG) sites).
                      Trial activation is planned for December 2025. The inclusion
                      duration is 3 years, total study duration is approximately
                      130 months (10.8 years).CONCLUSIONVIGOR (EORTC-2427-BTG)
                      will investigate the efficacy and safety of adding
                      maintenance vorasidenib after completion of
                      radiochemotherapy in patients with newly diagnosed
                      astrocytoma, IDH-mutant, WHO grade 2 or 3. If the trial is
                      positive, this has the potential to become a new standard of
                      care.CLINICAL TRIAL REGISTRATION2024-519404-27-00
                      (EudraCT-number).FUNDINGServier.},
      month         = {Nov},
      date          = {2025-11-20},
      organization  = {7th Quadrennial Meeting of the World
                       Federation of Neuro-Oncology Societies,
                       Honolulu (USA), 20 Nov 2025 - 23 Nov
                       2025},
      cin          = {INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-4-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)1},
      doi          = {10.1093/neuonc/noaf201.0506},
      url          = {https://juser.fz-juelich.de/record/1053900},
}